Lv1
48 积分 2026-08-10 加入
Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes
21天前
已完结
Risk of Alzheimer's Disease and Alzheimer's Disease‐Related Dementias with liraglutide compared to semaglutide and dulaglutide in veterans with type 2 diabetes: An emulated clinical trial observational study
21天前
已完结
Reducing Alzheimer’s Disease Risk in Diabetes: Synergistic Effects of Metformin, GLP-1 Receptor Agonists, and SGLT2 Inhibitors
21天前
已关闭
Glucagon-like Peptide-1 Receptor Agonists vs. Sodium-glucose Cotransporter 2 Inhibitors and Risk for Dementia in Individuals with Diabetes: A Propensity-weighted, Population-based Cohort Study
21天前
已完结
Cognitive Outcomes Associated with Antidiabetic Medications in Patients with Type 2 Diabetes
21天前
已完结
Mapping the effectiveness and risks of GLP-1 receptor agonists
1个月前
已完结
Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
1个月前
已完结
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
1个月前
已完结
Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study
1个月前
已完结
Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer's disease, vascular dementia, and other dementia types among patients with type 2 diabetes
1个月前
已完结
皖公网安备34019202002308
